- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04371627
Viaskin® Peanut (DBV712) Expanded Access Protocol
May 26, 2021 updated by: DBV Technologies
Viaskin® Peanut (DBV712) Expanded Access Protocol in Peanut-Allergic Children
This is an open label expanded access program for male and female patients ≥ 4 years old.
Study Overview
Detailed Description
This study is an open-label Intermediate-size EAP designed to provide treatment access for eligible Peanut-Allergic Children.
This EAP entails visits every three months to assess patient status, safety, and to provide drug supply.
Viaskin® Peanut treatment will continue until, in the clinical judgment of the Investigator, the patient is no longer benefiting from continuation of the treatment, the drug becomes approved and available by prescription, or the study is terminated.
Study Type
Expanded Access
Expanded Access Type
- Intermediate-size Population
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
4 years to 12 years (CHILD)
Accepts Healthy Volunteers
N/A
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female ≥ 4 years of age
- Prior participation in a Viaskin® Peanut REALISE or PEOPLE clinical study for peanut-allergic patients
Exclusion Criteria:
- Pregnancy or lactation or planning a pregnancy.
- Generalized dermatologic disease (for example, active atopic dermatitis, uncontrolled generalized active eczema, ichthyosis vulgaris) extending widely on the skin and especially on the back with no intact zones to apply the Viaskin® patches.
- Patients who developed hypersensitivity to excipients of the Viaskin® patches.
- Received or planning to receive anti-tumor necrosis factor drugs or anti-IgE drugs (such as omalizumab) or any biologic immunomodulatory therapy.
- Receiving or planning to receive any other type of immunotherapy to any food (for example, EPIT, OIT, or SLIT or specific oral tolerance induction) or any aeroallergen or venom immunotherapy during their participation in the study.
- Use of cyclosporine or other immunosuppressive agents within 3 months before entering the study. Topical calcineurin inhibitors are permitted.
- A history of important non-compliance during the REALISE or PEOPLE studies. Important non-compliance includes patients not applying the patches for 60 or more days in total and/or for 30 or more consecutive days during the REALISE or PEOPLE studies.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
First Submitted
April 29, 2020
First Submitted That Met QC Criteria
April 29, 2020
First Posted (ACTUAL)
May 1, 2020
Study Record Updates
Last Update Posted (ACTUAL)
May 28, 2021
Last Update Submitted That Met QC Criteria
May 26, 2021
Last Verified
May 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- V712-EAP01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Peanut Allergy
-
Rima RachidUniversity of MinnesotaRecruitingPeanut Hypersensitivity | Peanut Allergy | Food Allergy | Food Allergy Peanut | Peanut-Induced Anaphylaxis | Allergy, PeanutUnited States
-
University of ManitobaThe Hospital for Sick Children; University of British Columbia; McGill UniversityEnrolling by invitationAllergy to Peanut
-
Scripps HealthThe Scripps Research InstituteWithdrawnFood Allergy PeanutUnited States
-
Novartis PharmaceuticalsTerminatedAllergy, PeanutUnited States, Germany, Japan, Australia, France, Spain, Denmark, Canada, Italy, Netherlands
-
Imperial College LondonUniversity of Sydney; National Institute for Health Research, United KingdomCompletedIgE Mediated Peanut AllergyUnited Kingdom
-
King's College LondonCharite University, Berlin, Germany; University Hospital, Bonn; Institut Curie; Levantine UKNot yet recruitingAllergy;Food | Food Allergy Peanut | Pathways and Sources of Exposure
-
Imperial College LondonUniversity College CorkActive, not recruitingPeanut Hypersensitivity | IgE Mediated Peanut AllergyUnited Kingdom
-
National Institute of Allergy and Infectious Diseases...Genentech, Inc.; Novartis Pharmaceuticals; Rho Federal Systems Division, Inc.Active, not recruitingPeanut Allergy | Multi-food AllergyUnited States
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
Scott SichererNational Institute of Allergy and Infectious Diseases (NIAID)CompletedPeanut Allergy | Food AllergyUnited States
Clinical Trials on Viaskin Peanut
-
DBV TechnologiesCompletedPeanut AllergyUnited States, Netherlands, France, Canada, Poland
-
DBV TechnologiesActive, not recruitingPeanut AllergyUnited States, Canada, Australia, France, Germany, United Kingdom, Ireland, Netherlands
-
DBV TechnologiesActive, not recruitingPeanut AllergyUnited States, Germany, Canada, Australia, Ireland
-
DBV TechnologiesCompletedPeanut AllergyUnited States, Netherlands, France, Canada
-
DBV TechnologiesCompletedPeanut AllergyUnited States
-
DBV TechnologiesCompletedPeanut AllergyUnited States, Canada
-
DBV TechnologiesTodd D. Green MD, DBV TechnologiesAvailablePeanut AllergyUnited States
-
DBV TechnologiesCompletedPeanut AllergyUnited States, Canada, Germany, Australia, Ireland
-
DBV TechnologiesCompletedFood AllergyUnited States, Canada
-
National Institute of Allergy and Infectious Diseases...Consortium of Food Allergy ResearchCompletedHypersensitivity | Food Hypersensitivity | Hypersensitivity, Immediate | Peanut HypersensitivityUnited States